About palbociclib
Cyclin-dependent kinase 4/6 inhibitor
Used for
- With other cancer medicines for certain hormone receptor-positive, HER2-negative advanced breast cancers.
Usual adult dose
125 mg by mouth once daily for 21 days, followed by 7 days off, in 28-day cycles; taken with an aromatase inhibitor or fulvestrant.
Common side effects
- Low white blood cell counts and infection risk
- Anemia and low platelet counts
- Tiredness
- Nausea, mouth sores, or diarrhea
Important warnings
- Blood counts require regular monitoring; treatment may need interruption or dose reduction.
- Seek urgent care for fever or signs of infection.
- Avoid grapefruit and Seville oranges; they can raise palbociclib levels.
- May cause lung inflammation; report new or worsening breathing problems.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least 3 weeks after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin, can raise levels.
- Strong CYP3A inducers, such as rifampin, can lower levels.
- Can increase levels of some CYP3A substrates, including certain statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.